Clinical Trials Logo

Cancer of Unknown Primary Site clinical trials

View clinical trials related to Cancer of Unknown Primary Site.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05263700 Recruiting - Clinical trials for Cancer of Unknown Primary Site

FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary

FAPI-CUP
Start date: February 23, 2022
Phase: N/A
Study type: Interventional

This is a prospective single arm cohort study designed to evaluate the diagnostic ability of 68Ga-FAPI-PET/CT scan in determining likely tissue of origin in Cancer of Unknown Primary (CUP) patients not identified by standard of care. Patients with CUP will be either treatment naïve or starting second-line treatment.

NCT ID: NCT04969835 Recruiting - Breast Cancer Clinical Trials

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

Start date: July 16, 2021
Phase: Phase 1
Study type: Interventional

This open-label, First-into-Human (FIH) study will evaluate the safety, tolerability, pharmacokinetics (PK) and early efficacy of AVA6000, a FAP-activated pro-drug of doxorubicin, in patients with locally advanced and/or metastatic solid tumours. In Phase Ia, using a 3+3 design, escalating doses of AVA6000 will be administered to patients with a range of solid tumour types to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D). In Phase 1b, the selected RP2D dose will be assessed in one to three tumour types.

NCT ID: NCT04952103 Recruiting - Clinical trials for Cancer of Unknown Primary Site

Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China

Start date: June 18, 2021
Phase:
Study type: Observational

This study is a prospective, real world study.The objective is to observe the diagnosis and first-line treatment of Chinese patients with cancer of unknown primary, and collect the clinicopathological characteristics, treatment outcomes, survival and other data of the patients.

NCT ID: NCT04504604 Recruiting - Cholangiocarcinoma Clinical Trials

TCF-001 TRACK (Target Rare Cancer Knowledge) Study

TRACK
Start date: October 1, 2020
Phase: N/A
Study type: Interventional

This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.

NCT ID: NCT04459273 Recruiting - Clinical trials for Hepatocellular Carcinoma

Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers

FAPI PET RDRC
Start date: August 27, 2020
Phase: Phase 1
Study type: Interventional

This exploratory study investigates how an imaging technique called 68Ga-FAPi-46 PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with cancer. Because some cancers take up 68Ga-FAPi-46 it can be seen with PET. FAP stands for Fibroblast Activation Protein. FAP is produced by cells that surround tumors (cancer associated fibroblasts). The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the future provide additional information about various cancers.

NCT ID: NCT04131621 Recruiting - Clinical trials for Cancer of Unknown Primary Site

Nivolumab/Ipilimumab in Second Line CUP-syndrome

CheCUP
Start date: December 12, 2019
Phase: Phase 2
Study type: Interventional

To compare the efficacy of nivolumab plus ipilimumab in subjects with high vs. Intermediate/low TMB poor-prognosis CUP (non-specific subset) who are relapsed or refractory to platinum-based first-line chemotherapy. To evaluate the efficacy of nivolumab plus ipilimumab in subjects with poor-prognosis CUP (non-specific subset) who are relapsed or refractory to platinum-based first-line chemotherapy